Hi, my name is Tappan Khadiyya. I'm currently professor of the department leukemia at MD Anderson Cancer Center. Really happy to be here at the ASH meeting interacting with my colleagues, listening to new data and presenting some of our own data. I want to highlight one of our abstracts, which is actually first authored by one of my colleagues, Dr. Alexander Bazinet, and which I'm presenting for him. It's an all-oral combination of chemotherapy for patients with newly diagnosed AML, specifically those patients who are 75 years of age or older, or those patients who are unfit for intensive chemotherapy, who have advanced performance status, those folks who just can't tolerate the intensive chemotherapy approach. Based on the Viali-A study, which combined IV or sub-QA society and VEN, we knew that the combination of HMA and VEN was going to be active. So we used an oral formulation of decitabine, which is oral decitabine or ASTX, combined with venetoclax. In newly diagnosed patients with AML who are unfit for intensive chemotherapy, we saw a remission rate of 67%, very similar to Viali-A, and immediate overall survival of 12.6 months. Again, excellent overall survival in this population. What you need to know, though, is this population of patients, although older and similar to Viali-A, were enriched for patients with adverse prognostic features, including those who had adverse karyotype, adverse mutations, as well as 40% of the patients who had received prior HMA or hypomethaling ages for MDS prior to being diagnosed with AML. We know that in that patient population, the response is typically very low, and the survival is in the range of around five to six months. So in this sort of mixed population, we saw outstanding results, excellent remission rate, good tolerability in an all-oral regimen, portable, outpatient for the most part, that we can deliver to patients for induction of their maintenance.
HealthTree • December 10, 2023